de Jong EK, Geerlings MJ, den Hollander AI. Age-related macular degeneration. Genetics and Genomics of Eye Disease: MA, USA: Elsevier; Academic Press, 2020. p. 155–80.

Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–25.

CAS  PubMed  Article  Google Scholar 

Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.

CAS  PubMed  Article  Google Scholar 

Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009;89:607–48.

CAS  PubMed  Article  Google Scholar 

Falavarjani KG, Nguyen QJE. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787–94.

PubMed  Article  CAS  Google Scholar 

Bakri SJ, Thorne JE, Ho AC, Ehlers JP, Schoenberger SD, Yeh S, et al. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the american academy of ophthalmology. Ophthalmology. 2019;126:55–63.

PubMed  Article  Google Scholar 

Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70–5.

CAS  PubMed  Article  Google Scholar 

Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados IJR. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections. Retina. 2009;29:313–8.

PubMed  Article  Google Scholar 

Tolentino MJSoo. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113.

Article  Google Scholar 

Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.

CAS  PubMed  Article  Google Scholar 

Guimaraes TAC, Georgiou M, Bainbridge JWB, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br J Ophthalmol. 2021;105:151–7.

PubMed  Article  Google Scholar 

Arepalli S, Kaiser PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitreous. 2021;7:55.

PubMed  PubMed Central  Article  Google Scholar 

Pecen PE, Kaiser PK. Current phase 1/2 research for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2015;26:188–93.

PubMed  Article  Google Scholar 

He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clin Sci (Lond). 2015;128:805–23.

Article  Google Scholar 

Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NK, Rivers HM. Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res. 2019;36:29.

Article  CAS  Google Scholar 

Naso MF, Tomkowicz B, Perry WL, Strohl WRJB. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chen HJWJoMG. Adeno-associated virus vectors for human gene therapy. World J Med Genet. 2015;5:28–45.

Article  Google Scholar 

Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther. 2001;12:2029–32.

CAS  PubMed  Google Scholar 

Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167–76.

CAS  PubMed  Article  Google Scholar 

Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015;386:2395–403.

CAS  PubMed  Article  Google Scholar 

Constable IJ, Pierce CM, Lai CM, Magno AL, Degli-Esposti MA, French MA, et al. Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration. EBioMedicine. 2016;14:168–75.

PubMed  PubMed Central  Article  Google Scholar 

Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, et al. Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. Hum Gene Ther. 2017;28:99–111.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Binley K, Widdowson PS, Kelleher M, de Belin J, Loader J, Ferrige G, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther. 2012;23:980–91.

CAS  PubMed  Article  Google Scholar 

Kumar-Singh R. The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. Exp Eye Res. 2019;184:266–77.

CAS  PubMed  Article  Google Scholar 

Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS ONE. 2011;6:e19078.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc‐fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4:1015–28.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35:235–54.

CAS  PubMed  Article  Google Scholar 

Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9:15–32.

CAS  PubMed  Article  Google Scholar 

Kim HS, Kim I, Zheng L, Vernes J-M, Meng YG, Spiess C, editors. Evading pre-existing anti-hinge antibody binding by hinge engineering. MAbs. 2016;8:1536–47.

Huang T, Mathieu M, Lee S, Wang X, Kee YS, Bevers JJ, et al. Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells. J Biol Chem. 2018;293:906–19.

CAS  PubMed  Article  Google Scholar 

Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, et al. Engineering upper hinge improves stability and effector function of a human IgG1. J Biol Chem. 2012;287:5891–7.

CAS  PubMed  Article  Google Scholar 

Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019;10:1296.

CAS  PubMed  PubMed Central  Article  Google Scholar 

D’Eall C, Pon RA, Rossotti MA, Krahn N, Spearman M, Callaghan D, et al. Modulating antibody‐dependent cellular cytotoxicity of epidermal growth factor receptor‐specific heavy‐chain antibodies through hinge engineering. J Immunol. 2019;177:1129–38.

Google Scholar 

Dall’Acqua WF, Cook KE, Damschroder MM, Woods RM. Wu HJTJoI. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006;177:1129–38.

PubMed  Article  Google Scholar 

Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009;16:10–6.

CAS  PubMed  Article  Google Scholar 

Bagley RG, Kurtzberg L, Weber W, Nguyen T-H, Roth S, Krumbholz R, et al. sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011;10:404–15.

CAS  PubMed  Article  Google Scholar 

Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–67.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 2011;19:260–5.

CAS  PubMed  Article  Google Scholar 

Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390:50–61.

CAS  PubMed  Article  Google Scholar 

Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AMJC. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997;91:695–704.

CAS  PubMed  Article  Google Scholar 

Davari M, Soheili Z-S, Samiei S, Sharifi Z, Pirmardan ER. Overexpression of miR-183/-96/-182 triggers neuronal cell fate in Human Retinal Pigment Epithelial (hRPE) cells in culture. Biochem Biophys Res Commun. 2017;483:745–51.